Please select the option that best describes you:
In which patient population diagnosed with CLL would you still treat with the FCR (fludarabine, cyclophosphamide, rituximab) regimen?
In young and fit patients with mutated IGHV, is the FCR regimen still better than newer regimens such as obinutuzumab + venetoclax?